For instance, a recently published patent CN117050134 describes the synthesis and characterization of a novel oleanamide derivative for activating KEAP/NRF2/ARE signaling pathway which is a signature of oxidative stress. This treatment activates NRF2 transcription factor that can help in preventing and treating various neurological disorders including ALS. In context of HD, WO2023099648 by AstraZeneca AB, Sweden, describes pyrazolo-and triazolo-azinone compounds that inhibits receptor-interacting protein kinase 1 (RIPK1) and can be used in the treatment of neurological disorders including HD. In another example, patent application WO2023236967A1 by RemeGen Co., Ltd., China, describes the development of the drug, a dosage regimen, an administration interval, and a mode for treating MG using -Telitacicept (TACI-Fc fusion protein).